阻塞性睡眠呼吸暂停和痴呆症:一个角色?
1Sorbonne University, CNRS, UMR Biological Adaptation and Aging, AP-HP, Paris, France; Charles-Foix Hospital, Functional Exploration Unit for Older Patients, 94200 Ivry-sur-Seine, France.
Revue neurologique
|August 26, 2023
概括
阻塞性睡眠呼吸暂停 (OSA) 在老年人中很常见,与阿尔茨海默病 (AD) 生物标志物和认知能力下降有关. 需要进一步的研究来确定治疗OSA是否会影响AD的进展.
科学领域:
- 神经学 神经学
- 睡眠医学 睡眠医学
- 老年学是一门学科.
背景情况:
- 在人类和动物模型中,越来越多的证据将睡眠障碍与阿尔茨海默病 (AD) 病理生理学联系起来.
- 阻塞性睡眠呼吸暂停 (OSA) 是中年和老年人群中普遍存在的并发症,通常与认知障碍和痴呆风险增加有关,包括AD.
- 与认知正常的老年人相比,OSA在患有AD的个体中更频繁地观察到.
研究的目的:
- 探索阻塞性睡眠呼吸暂停 (OSA) 和阿尔茨海默病 (AD) 之间的联系.
- 了解OSA在AD病理生理学中的作用及其对认知衰退的潜在影响.
- 调查OSA,AD生物标志物之间的联系,以及OSA查和治疗的潜在好处.
主要方法:
- 关于睡眠障碍,认知障碍和阿尔茨海默病的现有文献的综述.
- 分析研究的研究,调查OSA在AD患者与认知正常个体之间的患病率.
- 审查关于OSA和AD生物标志物之间的关系的研究.
主要成果:
- OSA与认知障碍,白天嗜睡,以及患轻度认知障碍,痴呆症和AD的风险增加有关.
- 在OSA和已确定的AD生物标志物之间存在相关性.
- 在患有AD的老年人中,OSA的患病率更高.
结论:
- OSA是与阿尔茨海默氏症相关的显著并发症,影响认知功能和潜在的AD生物标志物.
- 需要进一步调查,以确定是否查和治疗OSA可以积极影响AD生物标志物,并减缓或预防痴呆.
- 了解OSA在AD中的作用对于制定延迟或预防疾病发病的策略至关重要,因为缺乏有效的AD治疗方法.
更多相关视频
相关概念视频
Sleep Apnea
184
Sleep apnea is a condition where breathing stops intermittently during sleep, often leading to significant health issues. Each episode can last from 10 to 20 seconds or more and is frequently accompanied by a brief arousal from sleep. This disturbance, largely unnoticed by the individual, can lead to severe daytime fatigue. Commonly, individuals seek help after being informed by their partners about loud snoring and noticeable breathing pauses during sleep.
The condition is more prevalent among...
The condition is more prevalent among...
184
Dementia
139
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
139
Alzheimer's Disease: Overview
517
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
517
REM Sleep Behavior Disorder
248
REM Sleep Behavior Disorder (RBD) is a sleep disorder characterized by the absence of muscle paralysis that normally occurs during the REM phase of sleep. This absence allows individuals to physically act out their dreams, which are often vivid and disturbing. Common behaviors exhibited during episodes include kicking, punching, and yelling. These actions can be dangerous, potentially leading to injuries for the person with RBD or their bed partner.
RBD is significantly associated with...
RBD is significantly associated with...
248
Sleep-Wake Cycles
1.4K
Sleep is an essential physiological process vital to maintaining overall well-being. The reticular activating system (RAS), a network of neurons in the brainstem, regulates wakefulness and sleep. While it may seem passive, sleep consists of distinct cycles, each with its unique characteristics and functions. Two key sleep phases are non-rapid eye movement (NREM) and rapid eye movement (REM).
NREM Sleep
NREM sleep comprises four progressive stages that seamlessly merge:
NREM Sleep
NREM sleep comprises four progressive stages that seamlessly merge:
1.4K
Alzheimer's Disease: Treatment
212
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212


